Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a Beta-3 adrenergic agonist presented as an oral dosage form for oral use. It is indicated for the management of overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients.

GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron acts on the bladder’s β3‑adrenergic receptors to improve storage symptoms in overactive bladder and related conditions. - Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daily voids. - Urge urinary incontinence: lowers the incidence of involuntary leakage.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient head pain of varying intensity. - Constipation: reduced bowel motility leading to hard stools.

Serious or Rare Side Effects: - Severe hypertension: marked increase in blood pressure requiring medical intervention. - Urinary retention: difficulty emptying the bladder that may need catheterisation. - Angle‑closure glaucoma: acute increase in intra‑ocular pressure presenting with eye pain and visual disturbance.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: check baseline and periodic readings. - Assess renal function: dose adjustment may be needed in impairment. - Review concomitant medications: especially other agents affecting bladder tone. - Use caution in uncontrolled hypertension: avoid if systolic >180 mmHg. - Avoid in severe hepatic impairment: limited data on safety. - Store at room temperature: keep in the original pack, protect from moisture.

Mirabegron can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine): may increase mirabegron exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole): can raise plasma levels. - Combined anticholinergics: may exacerbate urinary retention.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect when blood pressure falls. - Antihypertensives: monitor for additive blood‑pressure lowering. - Other β3‑agonists: concurrent use may increase risk of cardiovascular effects.